Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-18T12:59:26.606Z Has data issue: false hasContentIssue false
  • English
  • Français

Two-year outcomes of moderately hypofractionated 70 Gy in 28 fractions, intensity-modulated radiotherapy and volumetric modulated arc therapy for localised prostate cancer

Published online by Cambridge University Press:  15 April 2020

Cindy Sharon Ortiz Arce ,
Cristian Salvador Leon Solorio ,
David Calderon Mendoza ,
Jose de Jesus Ornelas Lopez ,
Ana Luisa Nava Sierra ,
Placido Domingo Esqueda Guerrero ,
Rosalia Souto del Bosque ,
Alejandro Rodríguez Camacho ,
Jose Alais Cruz Cruz  and
Juan Antonio Reyes Nava
...Show all authors
Cindy Sharon Ortiz Arce
Affiliation:
Radiotherapy service, Mexican Social Security Institute, Bajio High Specialty Hospital, Ciudad de Mexico, Mexico
Cristian Salvador Leon Solorio
Affiliation:
Radiotherapy service, Mexican Social Security Institute, Bajio High Specialty Hospital, Ciudad de Mexico, Mexico
David Calderon Mendoza
Affiliation:
Radiotherapy service, Mexican Social Security Institute, Bajio High Specialty Hospital, Ciudad de Mexico, Mexico
Jose de Jesus Ornelas Lopez
Affiliation:
Radiotherapy service, Mexican Social Security Institute, Bajio High Specialty Hospital, Ciudad de Mexico, Mexico
Ana Luisa Nava Sierra
Affiliation:
Radiotherapy service, Mexican Social Security Institute, Bajio High Specialty Hospital, Ciudad de Mexico, Mexico
Placido Domingo Esqueda Guerrero
Affiliation:
Radiotherapy service, Mexican Social Security Institute, Bajio High Specialty Hospital, Ciudad de Mexico, Mexico
Rosalia Souto del Bosque
Affiliation:
Radiotherapy service, Mexican Social Security Institute, Bajio High Specialty Hospital, Ciudad de Mexico, Mexico
Alejandro Rodríguez Camacho
Affiliation:
Radiotherapy service, Mexican Social Security Institute, Medical Center XXI Century, Ciudad de Mexico37160, Mexico
Jose Alais Cruz Cruz
Affiliation:
Radiotherapy service, Mexican Social Security Institute, Bajio High Specialty Hospital, Ciudad de Mexico, Mexico
Juan Antonio Reyes Nava
Affiliation:
Radiotherapy service, Mexican Social Security Institute, Bajio High Specialty Hospital, Ciudad de Mexico, Mexico
Alejandro Olmos Guzman*
Affiliation:
Radiotherapy service, Mexican Social Security Institute, Bajio High Specialty Hospital, Ciudad de Mexico, Mexico
*
Author for correspondence: Alejandro Olmos Guzman, Radiotherapy department, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Mexico. Tel: 5531075073. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction:

Standard external beam radiotherapy is a treatment option for patients with localised prostate cancer and is used in patients with low-, intermediate- and high-risk disease with androgen deprivation according to the risk of the disease. In the last few years, hypofractionated radiotherapy has been demonstrated to be as safe as standard radiotherapy if given over a shorter time than standard radiotherapy with larger doses per fraction. External radiotherapy for localised prostate cancer typically delivers 37–42 fractions of 1·8–2·0 Gy per fraction given 5 days per week over 7·5–8·5 weeks. Hypofractionated radiotherapy delivers 20–28 fractions of 2·5–2·6 Gy per fraction given 5 days per week over 4–5·6 weeks.

Methods:

A retrospective analysis of assessment of 30 patients was undertaken from 2016 to 2018. The aim of this study was to evaluate the 2-year outcomes of 30 patients with prostate cancer treated with hypofractionated radiotherapy 70 Gy in 28 fractions.

Results:

Biochemical failure with hypofractionated radiotherapy was found in a total of 20% of patients. In the classification by risk groups, there were no biochemical failures in low-risk patients; in the low intermediate course, 3·3% of patients; in the high intermediate group, 3·3% patients; and in the high-risk group, the largest documented biochemical failure was in 13·3% of patients. For acute urinary toxicity, grade I was 56·6%; grade II, 6·6%. For acute rectal toxicity, grade I was 46·6%; grade II, 3·3%.

Conclusion:

This is one of the first studies of hypofractionated radiotherapy in prostate cancer in Latin America, and the results of this study demonstrated that the outcomes were similar to the standard regimen in all risk groups.

Keywords

biochemical failurehypofractionatedprostate cancer
Type
Case Study
Information
Journal of Radiotherapy in Practice , Volume 20 , Issue 2 , June 2021 , pp. 242 - 244
Check for updates
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

National Comprehensive Cancer Network: Prostate cancer, 2019. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (last date accessed 12 December 2019).Google Scholar
Brenner, D J, Hall, E J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095–1101.CrossRefGoogle ScholarPubMed
Brenner, D J, Martinez, A A, Edmundson, G K, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52: 6–13.CrossRefGoogle Scholar
Dearnaley, D P, Sydes, M R, Graham, J D, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475–487.CrossRefGoogle ScholarPubMed
Kuban, D A, Tucker, S L, Dong, L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J RadiatOncol Biol Phys 2008; 70: 67–74.CrossRefGoogle Scholar
Zietman, A L, Bae, K, Slater, J D, et al. Randomized trial comparing conventional-dosewith highdose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010; 28: 1106–1111.CrossRefGoogle Scholar
Lee, W R, Dignam, J J, Amin, M B, et al. Randomised phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 2016; 34: 2325–2332.CrossRefGoogle Scholar
Catton, C N, Lukka, H, Gu, C-S, et al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol 2017; 35: 1884–1890.CrossRefGoogle ScholarPubMed
Abu-Gheida, Ibrahim, Reddy, Chandana A., Kotecha, Rupesh, et al. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer. International Journal or Radiation Oncology 2019; 104: 325–333.CrossRefGoogle ScholarPubMed
Hoffman, KE, Voong, KR, Levy, LB, et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. J Clin Oncol 2018; 36: 2943–2949.CrossRefGoogle ScholarPubMed
Partin, AW, Kattan, MW, Subong, EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update. JAMA 1997; 277: 1445–1451.CrossRefGoogle Scholar
Martin, J, Frantzis, J, Chung, P, et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (A TROG-OCOG Intergroup Project). Radiother Oncol 2013; 107: 333–338.CrossRefGoogle Scholar
https://www.rtog.org/ResearchAssociates/AdverseEventReporting/CooperativeGroupCommonToxicityCriteria.aspx (last date accessed 20 December 2019).Google Scholar
Dearnaley, D, Syndikus, I, Mossop, H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, noninferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047–1060.CrossRefGoogle Scholar
Pollack, A, Walker, G, Horwitz, EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013; 31: 3860–3868.CrossRefGoogle ScholarPubMed